News | October 10, 2013

Study Published in Journal of Clinical Oncology

PET systems nuclear imaging oncology related journal of clinical university

October 10, 2013 — Advanced imaging with Positron Emission Tomography (PET) scans shows promise in predicting which patients with inoperable lung cancer have more aggressive tumors and need additional treatment following standard chemotherapy/radiation therapy, according to research published online in the Journal of Clinical Oncology (JOC).

The multi-site trial, led by study author and principal investigator Mitch Machtay, M.D., University Hospitals Seidman Cancer Center, enrolled 250 patients at 60 cancer centers around the country. The National Cancer Institute funded the trial and was led by the American College of Radiology Imaging Network (ACRIN) in collaboration with Radiation Therapy Oncology Group (RTOG).

“These findings have the potential to give cancer physicians a new tool to more effectively tailor treatments for patients with locally advanced lung cancer,” said Machtay, chairman, radiation oncology, University Hospitals Case Medical Center and Case Western Reserve University School of Medicine. “This cooperative group study determined that the PET scan can show us which patients have the most aggressive tumors, potentially enabling us to intensify their treatment.”

In this study, stage III lung cancer patients had PET scans before and after a combined treatment regimen of chemotherapy and radiation therapy. They measured how rapidly tumors absorbed a radioactive sugar molecule (FDG).

The researchers found that the post-treatment scan was predictive for patients’ prognosis by identifying that patients with high levels of FDG uptake following treatment had more aggressive tumors that were more likely to recur. The researchers found that the higher the standard uptake value (SUV) for FDG in the primary tumor, the greater the recurrence rate and the lower the survival rate of patients.

The results also showed that there was a strong correlation between the radiation dose intensity and local control of the cancer, indicating that further research needs to be conducted in radiation technology for lung cancer

For more information: www.jco.ascopubs.org


Related Content

News | Magnetic Resonance Imaging (MRI)

June 9, 2026 — An investigator at the Icahn School of Medicine at Mount Sinai has received international recognition for ...

Time June 15, 2026
arrow
News | PET-MRI

June 10, 2026 — UTHealth Houston has launched a state-of-the-art PET/MRI imaging service, bringing together two advanced ...

Time June 12, 2026
arrow
News | FDA

June 4, 2026 — GE HealthCare has received 510(k) clearance from the United States Food and Drug Administration (FDA) for ...

Time June 05, 2026
arrow
News | Nuclear Imaging

June 1, 2026 — At the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, GE HealthCare will ...

Time June 02, 2026
arrow
News | Radiopharmaceuticals and Tracers

June 1, 2026 — Serac Healthcare Ltd. has presented Phase 2 data showing that SPECT-CT imaging with the radiotracer 99mTc ...

Time June 01, 2026
arrow
News | Ultrasound Imaging

May 26, 2026 — A soft, wearable ultrasound patch that can continuously monitor a fetus for hours at a time — and it can ...

Time May 27, 2026
arrow
News | Radiopharmaceuticals and Tracers

May 27, 2026 — Subtle Medical has received FDA clearance for its SubtleHD (PET), the company's next-generation AI ...

Time May 27, 2026
arrow
News | Radiopharmaceuticals and Tracers

May 7, 2026 — Bayer has announced positive topline results from the Phase III REVEAL study, an investigator-initiated ...

Time May 08, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Contrast Agents

April 23, 2026 — On April 23, GE HealthCare announced the first patient has been dosed in the international, multi ...

Time April 23, 2026
arrow
Subscribe Now